Clinical trials: Allogenic Disease
Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells
Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
This phase I trial studies the side effects of donor natural killer (NK) cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or has not responded to treatment (refractory).
- Conditions
- Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04220684
- Testing
- Cytarabine Hydrochloride, Fludarabine, Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Sumithira Vasu
Kidney Cancer
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00853125
- Testing
- therapeutic allogeneic lymphocytes, sunitinib malate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Rutgers, The State University of New Jersey
Acute GVH Disease
MTX and Steroid for aGVHD Treatment
The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid treatment for acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Trial name
- NCT04677868
- Testing
- Methotrexate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Breast Cancer
Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers
The goal of this clinical research study is to find the highest tolerable dose of TGFBR-2 KO CD70 CAR NK (TRICK-NK) in combination with 2 doses of T-Dxd that can be given to participants who have advanced breast cancer.
- Trial name
- NCT07553390
- Testing
- TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells, Trastuzumab deruxtecan (T-DXd), Rimiducid
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Aplastic Anemia
Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia
The purpose of this study is to reduce the regimen related toxicities and transplantation related mortality after allogeneic stem cell transplantation in adult acquired aplastic anemia (AA), the trials of reduced dose of Cy along…
- Trial name
- CyATG-FluATG (NCT01145976)
- Testing
- Cy-ATG, Flu-ATG
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Cooperative Study Group A for Hematology
Haematological Malignancy
Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation
This is a prospective study of the safety and efficacy of nivolumab for the treatment of relapsed or residual haematological malignancies after allogeneic stem cell transplantation (alloSCT).
- Trial name
- NIVALLO (NCT03146468)
- Testing
- Nivolumab Injection
- Where
- Australia
- Volunteers
- 14 people
- Sponsor
- Melbourne Health
Autism Spectrum Disorder, Autism
Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study
This 12-month study tests whether AdiaVita (umbilical cord blood-derived stem cells and exosomes) plus glutathione improves autism symptoms more than glutathione alone in children ages 3-12.
- Conditions
- Autism Spectrum Disorder, Autism, ASD, Autism Spectrum Disorder (ASD)
- Trial name
- NCT07304440
- Testing
- Umbilical Cord Blood-Derived Stem Cells and Exosomes, Glutathione
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Adia Med of Winter Park LLC
Epstein-Barr Virus Infection, Cytomegalovirus Infections
TETRAVI Expanded Access Program
This Expanded Access Program (EAP) allows qualified physicians within Texas to obtain access to multivirus-specific cytotoxic T lymphocytes (VSTs) developed under Baylor College of Medicine's TETRAVI program (NCT04013802) for the…
- Conditions
- Epstein-Barr Virus Infection, Cytomegalovirus Infections, Adenovirus Infection, BK Virus Infection
- Trial name
- NCT07104591
- Testing
- HLA-matched VSTs (Multivirus-specific Cytotoxic T Lymphocytes)
- Sponsor
- Baylor College of Medicine
Acute Graft-versus-host Disease
A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)
The primary purpose of the study is to assess the safety and pharmacokinetics (PK) of GDC-8264 in participants with acute graft-versus-host disease (aGVHD).
- Trial name
- NCT05673876
- Testing
- GDC-8264
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Genentech, Inc.
Critical Limb Ischemia, Buerger's Disease
A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers Disease
This is an open label, non-randomized, dose ranging study to evaluate the safety and efficacy of different doses of Stempeucel in critical limb ischemia patients.
- Trial name
- NCT01484574
- Testing
- Allogeneic Mesenchymal Stem Cells
- Where
- 10 sites in India
- Volunteers
- 90 people
- Sponsor
- Stempeutics Research Pvt Ltd
Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU)
Safety and Preliminary Efficacy of TrophiPatch, an Adipose-Derived Stromal Cell Patch for Chronic Leg Ulcers
This study aims to evaluate the safety and effectiveness of an experimental biological dressing called TrophiPatch, applied to adults with chronic leg ulcers of diabetic or vascular orign.
- Trial name
- RESCUE-PATCH (NCT07048054)
- Testing
- TrophiPatch: allogeneic adipose-derived stromal cell patch
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- Nicolò Brembilla
Hypoplastic Left Heart Syndrome
Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome
This study is intended to evaluate the safety and feasibility of intramyocardial injection of allogeneic mesenchymal cells during the Bi-Directional Cavopulmonary Anastomosis (BDCPA) surgery for hypoplastic left heart syndrome…
- Trial name
- ELPIS (NCT02398604)
- Testing
- Allo-hMSCs
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Longeveron Inc.
Depression, Anxiety
Caregiver Burden and Distress in Hematopoeitic Stem Cell Transplant
The purpose of this study is to examine the impact that serving as a caregiver for a patient undergoing hematopoietic stem cell transplant has on the caregiver.
- Conditions
- Depression, Anxiety, Fatigue, Distress
- Trial name
- NCT01084694
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Northside Hospital, Inc.
Prostate Cancer
GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have…
- Trial name
- NCT00089856
- Testing
- Immunotherapy with allogeneic prostate vaccine, Chemotherapy (Taxotere and prednisone)
- Where
- 126 sites in United States, Belgium and 6 more
- Volunteers
- 626 people
- Sponsor
- Cell Genesys
SYSTEMIC SCLERODERMA, ALLOGENEIC MESENCHYMAL STEM CELLS
Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells
The main ailm of this phase I-II study is to evaluate toxicity and efficacy of allogenic mesenchymal stem cell therapy to treat severe systemic sclerosis.
- Conditions
- SYSTEMIC SCLERODERMA, ALLOGENEIC MESENCHYMAL STEM CELLS, ADULT
- Trial name
- MSC (NCT02213705)
- Testing
- INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Ocular Graft-versus-host Disease
Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.
To evaluate the safety and efficacy of Pro-ocular™ 1% topical gel administered twice daily for 70 days in reducing or eliminating symptoms and signs of chronic ocular GvHD.
- Trial name
- NCT03990051
- Testing
- Pro-ocular™ topical gel
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Glia, LLC
Hematological Malignancies
Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings
The present project aims at comparing two nonmyeloablative regimens currently used in 2 major HCT centers in the US for patients with HLA-matched related or unrelated donor: the one from the Seattle group consisting of 2 Gy TBI…
- Trial name
- NCT00603954
- Testing
- Conditioning regimen: TBI + Fludarabine, Conditioning regimen:TLI (8 Gy) + ATG
- Where
- 11 sites in Belgium, Netherlands
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Liege
Graft-versus-host Disease, Relapse
Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation
Infusion of Mesenchymal Stem Cell (MSC) at day of recovery after bone marrow transplant (BMT) for patients with AL, AA and MM for acute Graft-versus-host Disease (GVHD) prophylaxis and treatment.
- Trial name
- NCT01941394
- Testing
- Mesenchymal stem cells
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- National Research Center for Hematology, Russia
Myocardial Infarction
Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
The purpose of this study is to determine whether Allogeneic Cardiosphere-Derived Cells (CAP-1002) is safe and effective in decreasing infarct size in patients with a myocardial infarction.
- Trial name
- ALLSTAR (NCT01458405)
- Testing
- CAP-1002 Allogeneic Cardiosphere-Derived Cells
- Where
- 32 sites in United States
- Volunteers
- 135 people
- Sponsor
- Capricor Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
This is a non-randomised, open-label phase I study of an investigational medicinal product (IMP) consisting of a HLA-A*02:01 restricted HA-1H T cell receptor transduced T cell (MDG1021) immunotherapy for relapsed or persistent…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
- Trial name
- NCT04464889
- Testing
- MDG1021 dose 1, MDG1021 dose 2, MDG1021 dose 3
- Where
- Netherlands
- Sponsor
- Medigene AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.